<DOC>
	<DOCNO>NCT02334436</DOCNO>
	<brief_summary>The primary objective demonstrate safety efficacy DWP-450 ( Botulinum purify neurotoxin , Type A ) Injection treatment moderate severe glabellar line associate corrugator and/or procerus muscle activity adult subject</brief_summary>
	<brief_title>A Phase III Study Demonstrate Safety Efficacy DWP-450 Treat Glabellar Lines - EV-002</brief_title>
	<detailed_description>Three hundred twenty-four eligible subject randomly assign 3:1 receive DWP-450 placebo . Safety efficacy assess Days 2 , 7 , 14 , 30 , 90 , 120 150 . The primary efficacy end point assess effectiveness DWP-450 placebo Day 30 superiority design .</detailed_description>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Subjects adult , least 18 year age Subject able provide inform consent comply study instruction Subject moderate severe glabellar line maximum frown assess investigator use GLS Subject moderate severe glabellar line maximum frown assess subject use GLS Subject willing able complete entire course study Previous treatment botulinum toxin serotype area within last 6 month Previous treatment facial aesthetic procedure ( e.g . injection filler , chemical peeling , photo rejuvenation ) glabellar area within last 12 month Previous insertion permanent material glabellar area Planned treatment botulinum toxin serotype body region study period Any surgery glabellar area include surgical removal corrugator , procerus , depressor supercilii muscle combination , scar glabellar area surround area ( include eye brow ) Energybased cryotherapy base treatment facial muscle superior lateral canthus Any plan facial aesthetic procedure trial period , superior level lateral canthus ( subject continue usual skin care routine ) Subjects may respond 20 Units botulinum toxin ( e.g. , inability substantially lessen glabellar frown line even physically spread apart ) Marked facial asymmetry Ptosis eyelid and/or eyebrow , history eyelid and/or eyebrow ptosis History facial nerve palsy Excessive dermatochalasis , deep dermal scarring , thick sebaceous skin Any active infection area injection sit Medical condition may affect neuromuscular function ( e.g. , myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis ) Evidence recent alcohol drug abuse Medical psychiatric condition may increase risk associate study participation may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study Pregnant sexually active female subject childbearing potential willing use acceptable form contraception Known allergy hypersensitivity botulinum toxin preparation Participation another interventional clinical study within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>